JOB/MA/142  
 
4 May 2020 
(20-3422) Page: 1/173 
Committee on Market Access    
 
 
TRADE IN PHARMACEUTICAL PRODUCTS:  
CONSOLIDATED LIST OF PRODUCTS COVERED BY THE SECTORAL PHARMA AGREEMENT  
NOTE BY THE SECRETARIAT1 
1. This document  has been prepared by the Secretariat at the request of the Participants to the 
1994 "Trade in Pharmaceutical Products" (also known as the "Pharmaceutical Agreement", or the 
"Pharma Agreement") , which is a plurilateral sectoral initiative that was negotiate d on the margins 
of the Uruguay Round and resulted in the binding and elimination of tariffs in a large number of 
pharmaceutical products and the substances used to produce them.   
2. This note seeks to provide a comprehensive overview of all products cove red by the initial 
agreement and its four subsequent reviews. It is being circulated for Members ’ information and 
reference only. For the first time, it  consolidates in a single list  the information contained in the 
following documents:  
1. The original 1994 P harma Agreement  (GATT document L/7430 and L/7430/Add.4) ; 
2. the results of the first review of the Pharma, which was , completed in October 1996  
(G/MA/W/10 ); 
3. The results of the second review, which was completed in November 1998  (G/MA/W/18 ); 
4. The results of the  third review, which was completed in February 2007  (G/MA/W/85 ); and  
5. The results of the fourth review, which was completed in August 2010  (G/MA/W/ 102). 
3. As a result of the Pharma Agreement and its reviews, WTO Members participating in this 
sectoral agreement  agreed  to eliminate customs duties and all other duties and charges  within the 
meaning of Article II of the GATT 1994  in pharmaceutical products and in the chemical intermediates 
used in the production of pharmaceuticals . Such items include  the following : 
1. items classified (or classifiable) in HS Chapter 30;  
2. items classified (or classifiable) in HS headings 2936, 2937, 2939, and 2941, with the 
exception of dihydrostreptomycin and salts, esters, and hydrates thereof;  and 
3. items enumerated in one of the four following annexes2: 
I. Annex I: pharmaceutical active ingredients that bear an "international non -proprietary 
name" (INN) from the World Heal th Organization;  
II. Annex II: salts, esters, and hydrates of pharmaceutical products which are described 
by the combination of an INN active ingredient contained in Annex I with a prefix or 
suffix, as long as such salt, ester, or hydrate is classified in the same HS 6 -digit 
heading as the INN active ingredient;  
III. Annex III: salts, esters, and hydrates of INN active ingredients that are not classified 
in the same HS 6 -digit heading as the INN active ingredient;  and 
IV. Annex IV: additional products used for the production and manufacture of finished 
pharmaceuticals.  
4. These four Annexes were reproduced in this document for reference. Participants to the 
Pharma Agreement are encouraged to review these Annexes and inform the Secretariat about any 
 
1 This document has been prepared under the Secretariat's own responsibility and is without prejudice 
to the positions of Members or to their rights and obligations under the WTO.   
2 Each item listed in the annexes is indicated in its original form at the ti me of its inclusion into the 
respective  annexes.  JOB/MA/142  
 
- 2 - 
 
  possible corrections or comments. Each of the listed  items has been attributed a unique identification 
number ("WTO ID") to track more easily comments and possible corrections submitted by Pharma 
Participants . This document will be reviewed as many times as necessa ry to reflect any additional 
comments from Pharma participants  to the Secretariat.  
_______________  
  JOB/MA/142  
 
- 3 - 
 
  PP 3 – 173 Offset (PDF and Microsoft Excel file attached)